Litzow, M R
Fielding, A K
Luger, S M
Paietta, E
Ofran, Y
Rowe, J M
Goldstone, A H
Tallman, M S
Lazarus, H M
Article History
Received: 14 April 2016
Revised: 29 October 2016
Accepted: 2 November 2016
First Online: 5 June 2017
Competing interests
: MRL has received research funding support from Amgen. AF has served on Amgen advisory boards. HML has served as a speaker for Bristol Myers Squibb and as a speaker for Amgen and on Amgen advisory boards. SML has received honoraria from Novartis and research funding from Amgen and Ariad. The remaining authors declare no conflict of interest.